Literature DB >> 18797198

Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia.

Takuro Nishikawa1, Kiyoshi Kawakami, Takashi Kumamoto, Shiro Tonooka, Akiko Abe, Kiyoshi Hayasaka, Yasuhiro Okamoto, Yoshifumi Kawano.   

Abstract

SUMMARY: We report a 13-year-old male patient with Charcot-Marie-Tooth disease (CMT) type 2 who developed severe neuropathy because of vincristine (VCR) for his acute lymphoblastic leukemia. A clumsy gait, muscle weakness in his fingers, and inverted champagne bottlelike muscle in the lower limbs were noticed after remission induction treatment for acute lymphoblastic leukemia, which included VCR at a total dose of 8 mg/m. An electrophysiologic study showed an almost normal median motor nerve conduction velocity (approximately 50 m/s), markedly reduced M-wave amplitude and sensory disturbance. He was diagnosed as CMT type 2 based on his symptoms and electrophysiologic findings. His symptoms gradually worsened, and even after VCR was discontinued, he could not walk alone for 7 months. VCR has previously been considered to be relatively safe in CMT type 2, however, some patients with CMT type 2 might show severe neurologic toxicities, as seen in patients with CMT type 1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18797198     DOI: 10.1097/MPH.0b013e31816624a4

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  7 in total

1.  Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation.

Authors:  Tomonori Nakamura; Akihiro Hashiguchi; Shinsuke Suzuki; Kimiharu Uozumi; Shoko Tokunaga; Hiroshi Takashima
Journal:  Neurogenetics       Date:  2012-01-25       Impact factor: 2.660

2.  Delayed Diagnosis of Metastatic Ewing Sarcoma Masked by Charcot-Marie-Tooth Disease.

Authors:  Ines B Menjak; Abha Gupta; Michelle N Grinman
Journal:  J Adolesc Young Adult Oncol       Date:  2013-12-01       Impact factor: 2.223

3.  Successful treatment of nasopharyngeal cancer using radiotherapy with concurrent cetuximab in a patient with Charcot-Marie-Tooth disease.

Authors:  Alexandra Nicoleta Budure; Eric Winquist; David Palma; Rohann Jonathan Mark Correa
Journal:  BMJ Case Rep       Date:  2019-07-15

4.  Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1).

Authors:  Patrick P Hess; Monica S Ventura Ferreira; Benjamin Rolles; Martin Kirschner; Florian Holtbernd; Mareike Tometten; Tim H Brümmendorf; Fabian Beier
Journal:  Clin Case Rep       Date:  2022-05-05

Review 5.  Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.

Authors:  Nicolas Kerckhove; Aurore Collin; Sakahlé Condé; Carine Chaleteix; Denis Pezet; David Balayssac
Journal:  Front Pharmacol       Date:  2017-02-24       Impact factor: 5.810

Review 6.  Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.

Authors:  Kjeld Schmiegelow; Klaus Müller; Signe Sloth Mogensen; Pernille Rudebeck Mogensen; Benjamin Ole Wolthers; Ulrik Kristoffer Stoltze; Ruta Tuckuviene; Thomas Frandsen
Journal:  F1000Res       Date:  2017-04-07

Review 7.  The genetics of Charcot-Marie-Tooth disease: current trends and future implications for diagnosis and management.

Authors:  J Chad Hoyle; Michael C Isfort; Jennifer Roggenbuck; W David Arnold
Journal:  Appl Clin Genet       Date:  2015-10-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.